This study aims to examine the safety and efficacy of Allogenic Mesenchymal Stem Cells (MSCs) as an adjunctive treatment of treatment resistant bipolar depression. Patients will be assigned into a treatment or a placebo group.
Patients who participate in this study will receive a single dose of MSCs or a placebo injection and will be followed up for 26 weeks after this. Half the patients will be randomly assigned to the MSCs-group, half the patients to the placebo group. Neither the patient nor the study team will know which group the patients are in.